US-Nigerian Cancer Control Center for Research on Implementation Science and Equity (C3-RISE)

摘要 尼日利亚每年有大量可预防的癌症死亡。人乳头瘤病毒(HPV) 疫苗和乙肝疫苗都是基于证据的预防癌症的策略，但它们不是 在尼日利亚被广泛推广。这表明有必要采取创新的战略，利用 实施科学和利用非洲人口最多的国家尼日利亚的集体智慧。我们建议 美国-尼日利亚癌症控制中心实施科学和公平研究(C3-RISE)。我们的 总体任务分为两个部分：(A)使用参与性执行科学战略(即众包开放 号召和学徒)扩大HPV和乙肝疫苗的接种，以预防癌症；和(B)作为 执行科学方面的公平和能力建设中心，以促进对干预措施的理解 接受和维持预防癌症的循证干预措施。该项目汇集了一个 尼日利亚医学研究所(顶峰)多学科研究人员的杰出团队 联邦卫生研究组织，类似于美国国立卫生研究院(NIH)、圣路易斯大学和北方大学 在教堂山的卡罗莱纳。我们提出以下目标：(1)通过以下方式加快公平的癌症控制 开发、测试和改进参与式实施战略，以分散疫苗以预防 社区环境中的癌症；(2)提高C3-RISE的科学生产力 业务和科学监督；(3)支持创新研究和学者发展 经过培训，以加快尼日利亚循证癌症控制干预措施的接受和维持。 这些目标将通过一个由两个核心(行政、能力建设)组成的培养中心来实现 两项研究(研究1侧重于HPV疫苗接种，研究2侧重于乙肝疫苗接种)。我们的三个合作伙伴 各机构在四年前启动了一项参与性实施科学项目，直接向 尼日利亚国家健康指南，培训了231名学生，为43名教职员工提供了指导机会，以及 最终形成了世卫组织/TDR关于保健众包的实用指南(UH3HD096929)。这导致了最近一次 获得NCI R01奖励(R01-CA271033)，利用参与式实施科学开发创新 加强尼日利亚人乳头状瘤病毒服务的战略。C3-Rise将利用这一势头催化尖端技术 癌症研究、培训、社区参与和政策翻译。我们的项目将增进健康 公平，它与尼日利亚国家癌症控制计划保持一致，侧重于参与、能力 建筑和维护。此U54授权申请直接响应NIH、NCI和NIMH战略 优先事项。

ABSTRACT Nigeria has a substantial number of preventable cancer deaths each year. The human papillomavirus (HPV) vaccine and hepatitis B (HBV) vaccine are both evidence-based strategies to prevent cancer, but they have not been widely scaled up in Nigeria. This suggests the need for innovative strategies that leverage implementation science and tap the collective wisdom of Nigeria, Africa’s most populous country. We propose the “US-Nigerian Cancer Control Center for Research on Implementation Science and Equity (C3-RISE).” Our overall mission is two part: (a) use participatory implementation science strategies (i.e. crowdsourcing open calls and apprenticeships) to expand uptake of HPV and HBV vaccines for cancer prevention; and (b) serve as a hub for equity and capacity building in implementation science to advance the understanding of intervention uptake and sustainment of evidence-based interventions to prevent cancer. This project brings together an exceptional group of multi-disciplinary researchers from the Nigerian Institute of Medical Research (the apex federal health research organization, similar to the US NIH), St. Louis University, and the University of North Carolina at Chapel Hill. We propose the following aims: (1) To accelerate equitable cancer control by developing, testing, and refining participatory implementation strategies to decentralize vaccines to prevent cancer in community settings; (2) To enhance the scientific productivity of C3-RISE by providing overarching operational and scientific oversight; (3) To support innovative research and the development of scholars trained to accelerate the uptake and sustainment of evidence-based cancer control interventions in Nigeria. These aims will be accomplished by a nurturing hub of two cores (Administrative, Capacity Building) alongside two research studies (Study 1 focused on HPV vaccination, Study 2 on HBV vaccination). Our three partner institutions launched a participatory implementation science project four years ago that directly informed national Nigerian health guidelines, trained 231 students, provided mentorship opportunities to 43 faculty, and culminated in a WHO/TDR practical guide on crowdsourcing for health (UH3HD096929). This led to a recently awarded NCI R01 grant (R01-CA271033) that uses participatory implementation science to develop innovative strategies to enhance HPV services in Nigeria. C3-RISE will leverage this momentum to catalyze cutting-edge cancer research, training, community engagement, and policy translation. Our project will increase health equity, and it aligns with the Nigerian National Cancer Control Plan by focusing on participation, capacity building, and sustainment. This U54 grant application directly responds to NIH, NCI, and NIMH strategic priorities.